Allos Therapeutics granted U.S. Patent for FOLOTYN Allos Therapeutics, Inc. U.S. Patent No. 7,622,470 was released to Memorial-Sloan Kettering Cancer Center, SRI Southern and International Study Institute, and expires on November 24, 2025. Allos holds a special worldwide license from these organizations to develop and market FOLOTYN for all indications. Graboyes, senior vice president, general counsel of Allos Therapeutics.?.‘Commissioner Hamburg had not been appointed by President Obama to serve as the principle lobbyist for pharma.’ AHF’s demand Hamburg to step down can be in response to FDA’s complete stonewalling of requests for information regarding its cozy romantic relationship with drug companies. In a response to an AHF lawsuit on FDA’s refusal to disclose documents beneath the Freedom Of Details Take action, FDA claimed that the ‘premise that FDA’s review of a pending medication application should be transparent is also incorrect,’ and that ‘FDA’s drug review process is not a participatory process. ‘One can just presume that FDA’s shocking insufficient transparency is basically because Commissioner Hamburg provides something to cover.’ ‘We can not afford to hold back for medical and security of the American public to be put at further risk before taking action.